OncBioMune Gets Patent for Cancer Vaccine in Mexico

Pharmaceutical Investing

OncBioMune Pharmaceuticals obtained a patent from the Mexican Institute of Industrial Property protecting the intellectual rights of the company’s ProscaVax throughout Mexico until January 8, 2032.

OncBioMune Pharmaceuticals (OTCQB:OBMP) obtained a patent from the Mexican Institute of Industrial Property protecting the intellectual rights of the company’s ProscaVax throughout Mexico until January 8, 2032.
As quoted in the press release:

ProscaVax is a clinical-stage protein therapeutic cancer vaccine combining tumor-associated antigens with biological adjuvants to selectively target tumor cells without damage to healthy cells. OncBioMune’s intellectual property portfolio protecting ProscaVax and other technologies consists of 16 patents and patents pending spanning approximately 50 countries worldwide.
“This patent is particularly important given the Mexican markets are integral to our business model. We expect to announce the official commencement of our Phase 2/3 trial of ProscaVax for late-stage prostate cancer in Mexico any day now, so the timing of the new patent couldn’t be any better,” commented Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. “An aging population and widespread adoption of screening for prostate specific antigen have Mexico facing a prostate cancer dilemma with little alternatives free of unpleasant side effects. We are optimistic that ProscaVax can provide a safe and effective solution to the nation’s problem for years to come.”

Click here to read the full press release.

Source: www.marketwired.com

The Conversation (0)
×